tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Sustained Growth Beyond Patent Cliffs: Confidence in Novartis’ Pipeline-Driven Upside to 2030
PremiumRatingsSustained Growth Beyond Patent Cliffs: Confidence in Novartis’ Pipeline-Driven Upside to 2030
7d ago
Novartis’ treatment of progressive supranuclear palsy granted orphan designation
Premium
The Fly
Novartis’ treatment of progressive supranuclear palsy granted orphan designation
7d ago
Novartis downgraded to Hold from Buy at DZ Bank
Premium
The Fly
Novartis downgraded to Hold from Buy at DZ Bank
8d ago
Novartis: Resilient Core Performance and Medium-Term Pipeline Catalysts Support Buy Rating Despite Near-Term Guidance Softness
PremiumRatingsNovartis: Resilient Core Performance and Medium-Term Pipeline Catalysts Support Buy Rating Despite Near-Term Guidance Softness
14d ago
Buy Rating on Novartis: Near-Term Guidance Headwinds Outweighed by Resilient Fundamentals, Advancing Pipeline, and Supportive Valuation
Premium
Ratings
Buy Rating on Novartis: Near-Term Guidance Headwinds Outweighed by Resilient Fundamentals, Advancing Pipeline, and Supportive Valuation
14d ago
Novartis: Resilient Core Earnings, Conservative Guidance and Robust Pipeline Support Buy Rating and EPS Upside to 2030
Premium
Ratings
Novartis: Resilient Core Earnings, Conservative Guidance and Robust Pipeline Support Buy Rating and EPS Upside to 2030
14d ago
Novartis AG: Visible Earnings, Supportive Guidance and Attractive Risk‑Reward Underpin Buy Rating
PremiumRatingsNovartis AG: Visible Earnings, Supportive Guidance and Attractive Risk‑Reward Underpin Buy Rating
21d ago
Novartis initiated with a Buy at Citi
Premium
The Fly
Novartis initiated with a Buy at Citi
22d ago
AI Daily: Nvidia invests $2B in CoreWeave
Premium
The Fly
AI Daily: Nvidia invests $2B in CoreWeave
23d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100